Joshua M. Lang
YOU?
Author Swipe
View article: Figure S4 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Figure S4 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer Open
Figure S4. Biodistribution Study
View article: Supplementary Figure S1 from Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer
Supplementary Figure S1 from Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer Open
Supplemental Figure 1. Tumor mutation burden (TMB) per subtype (left) and BRCA2 somatic mutation or deep deletion status per subtype (right).
View article: Figure S1 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Figure S1 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer Open
Figure S1. Correlation of TACSTD2 with Prostate Cancer Cell Surface Markers.
View article: Supplementary Tables S1-S4 from Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer
Supplementary Tables S1-S4 from Intrinsic Molecular Subtypes of Metastatic Castration-Resistant Prostate Cancer Open
Supplemental Table 1: Median, Inter-Quartile Range (IQR), and 25th and 75th percentiles for Figure 2. Supplemental Table 2: Median, Inter-Quartile Range (IQR), and 25th and 75th percentiles for Figure 3. Supplemental Table 3: Proportions f…
View article: Figure S3 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Figure S3 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer Open
Figure S3. Scatter plot of gene expression for genes shown in Figure 3D isolated from matched anti-EPCAM vs anti-TROP-2 captured CTCs at the same timepoint.
View article: Figure S2 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Figure S2 from Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer Open
Figure S2. Capture Efficiency of TROP-2 Expressing Cell Lines.
View article: Quantifying partial pathological response rate in prostate cancer patients who underwent neoadjuvant chemotherapy using a novel morphometric approach
Quantifying partial pathological response rate in prostate cancer patients who underwent neoadjuvant chemotherapy using a novel morphometric approach Open
View article: Endoscopic Ultrasound With Fine-Needle Biopsy for Rare Pancreatic Metastasis: A Case Series of Neuroendocrine Transformation From Primary Prostate Cancer
Endoscopic Ultrasound With Fine-Needle Biopsy for Rare Pancreatic Metastasis: A Case Series of Neuroendocrine Transformation From Primary Prostate Cancer Open
Metastatic cancer to the pancreas is uncommon, accounting for only 2%–4% of pancreatic malignancies. Prostate cancer spreading to the pancreas is exceptionally rare. We present 2 cases of metastatic castration-resistant prostate cancer wit…
View article: Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels Open
Fragmentomics based analysis of cell-free DNA (cfDNA) has recently emerged as a method to infer epigenetic and transcriptional data. Many of these reports analyze whole genome sequencing (WGS) which is not readily available clinically. Tar…
View article: The characterization of variable new antigen receptors targeting FAP isolated from a novel immunized library
The characterization of variable new antigen receptors targeting FAP isolated from a novel immunized library Open
View article: Engineering the bone metastatic prostate cancer niche through a microphysiological system to report patient-specific treatment response
Engineering the bone metastatic prostate cancer niche through a microphysiological system to report patient-specific treatment response Open
View article: Microfluidic Characterization and Analysis of Circulating Tumor Cells From Patients With Metastatic Melanoma
Microfluidic Characterization and Analysis of Circulating Tumor Cells From Patients With Metastatic Melanoma Open
Circulating tumor cells (CTCs) can provide non‐invasive insight into how a cancer patient responds to therapy. Their role in disease monitoring of advanced melanoma patients treated with immune checkpoint inhibitors (ICI) is unknown. CTC p…
View article: OGDHL regulates tumor growth, neuroendocrine marker expression, and nucleotide abundance in prostate cancer
OGDHL regulates tumor growth, neuroendocrine marker expression, and nucleotide abundance in prostate cancer Open
As cancer cells evade therapeutic pressure and adopt alternate lineage identities not commonly observed in the tissue of origin, they likely adopt alternate metabolic programs to support their evolving demands. Targeting these alternative …
View article: Figure S9 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S9 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S9. Serum PSA and disease category by CTC phenotype for all samples.
View article: Figure S11 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S11 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S11. Luminal B phenotype is associated with activation of pathways associated with RB1 and PTEN loss.
View article: Figure S12 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S12 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S12. Pretreatment CTC and PSMA-PET characteristics in the 177Lu-PSMA-617 sub-study cohort.
View article: Figure 2 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure 2 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Gene expression of epithelial and prostate adenocarcinoma–associated genes across CTC phenotypes. A, Schematic of the CTC transcriptional phenotypes. B and C, Epithelial keratin (KRT8 and KRT18) gene expr…
View article: Supplementary Genesets from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Supplementary Genesets from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Supplementary Genesets includes prostate cancer specific genesets curated from published literature
View article: Figure S15 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S15 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S15. Longitudinal FOLH1 expression and pathway analysis of CTCs in the 177Lu-PSMA-617 sub-study cohort.
View article: Figure S1 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S1 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S1. Calibration of ESTIMATE tumor content prediction.
View article: Figure S3 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S3 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S3. Reproducibility of tumor/immune content assessment, gene expression and pathway scores.
View article: Figure 3 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure 3 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Luminal-B CTC phenotype is associated with poor prognosis and adverse clinical features. A, Serum PSA (ng/mL) at the time of CTC collection in the survival analysis subset (Low_CTC, n = 63; Low_prolif, n = 12; LumA,
View article: Figure S14 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S14 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S14. Luminal B phenotype is associated with higher MYC signaling and lower radiation response scores.
View article: Figure S10 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S10 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S10. Sample cDNA concentration and tumor fraction by CTC phenotype in the survival analysis subset.
View article: Figure 6 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure 6 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Cell-surface target expression is variable across CTC phenotypes. A, Heatmap of gene expression of cell-surface targets ordered by clustering in Fig. 1D. B–J, Cell-surface target expression by CTC phenotype for targets associ…
View article: Figure S2 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S2 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S2. RNA sequencing quality metrics
View article: Table 1 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Table 1 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Clinical characteristics of cohort and CTC phenotype groups.
View article: Figure S6 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S6 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S6. Expression of epithelial and prostate adenocarcinoma genes across CTC phenotypes for all samples.
View article: Figure 5 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure 5 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Luminal-B CTC phenotype and persistent PSMA expression are associated with poor response to 177Lu–PSMA-617. A, Clinical benefit rate (the best radiographic response of stable disease, partial response, or complete respons…
View article: Figure S7 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
Figure S7 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes Open
Figure S7. Expression of neuroendocrine genes across CTC phenotypes.